Better Therapeutics, Inc. BTTX
At closeNov 3, 2026, 4:00 PM EST
- YTD
- 0.00%
- 1 year
- 0.00%
- Market cap
- 5.45K
- EPS (ttm)
- -0.37
- Shares out
- 54.52M
- Forward P/E
- -0.01
- YTD return
- 0.00%
- 1-year return
- 0.00%
- Volume
- 500
- Avg volume
- 4.18K
- Open
- 0.0001
- Previous close
- 0.0001
- Day's range
- 0.0001 – 0.0001
- 52-week range
- 0.0001 – 0.0002
- Beta
- 2.13
- Analysts
- Buy
- Price target
- 5.25 (+5249900.0%)
- Earnings date
- Dec 26, 2024
1Y 0.0000 (0.00%)
Key statistics
- Enterprise value
- 8.18M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -15.56M
- Total cash
- 6.60M
- Total debt
- 14.31M
- Return on equity
- 0.00%
- Short % of float
- 6.21%
- 50-day average
- 0.11514
- 200-day average
- 0.349255
Analyst view
Consensus: buy
- Target (low)
- 1.50
- Target (mean)
- 5.25
- Target (high)
- 9.00
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Dec 26, 2024
Expected Dec 26, 2024. Consensus EPS estimate -0.12.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Dec 26, 2024 | Sep 1, 2024 | 0.00 | — | — | — |
| Oct 2, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Jul 4, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | 0.00 | -0.15 | — | — |
| Aug 9, 2023 | Jun 1, 2023 | -0.39 | -0.24 | +0.15 | +38.46% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 9, 2023 | Chardan Capital | reit | Buy | Buy |
| Aug 9, 2023 | Lake Street | main | Buy | Buy |
| Apr 13, 2023 | Lake Street | main | — | Buy |
| Mar 30, 2023 | Chardan Capital | main | — | Buy |
| Nov 14, 2022 | Chardan Capital | main | — | Buy |
| Jul 28, 2022 | Chardan Capital | main | — | Buy |
About Better Therapeutics, Inc.
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- bettertx.com
News
Click Therapeutics Accelerates Expansion into Obesity and Cardiometabolic Disease With Acquisition of the Assets of Better Therapeutics, Inc. 
Why Jabil Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Friday's Mid-Day Session 
12 Health Care Stocks Moving In Friday's Intraday Session 
Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket 
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session 
Better Therapeutics Announces it will Seek Strategic Alternatives and will be Delisted from Nasdaq 
Better Therapeutics Announces an Innovative Partnership with the American College of Lifestyle Medicine to Expand Access to AspyreRx Across 1,400 Federally Qualified Health Centers 
Better Therapeutics Announces Acceptance of Late Breaking Abstract for Its AspyreRx Pivotal Trial 180 Day Outcomes and Participation at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) 
Better Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV 
Better Therapeutics' (BTTX) CBT Gains FDA's Breakthrough Status
Your note
Sign in to keep a note on BTTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARMANINO ANDREW J | Director | Stock Award(Grant) | Dec 17, 2023 | 745,452 |
| BERMAN MARK A | Officer | Stock Award(Grant) | Dec 17, 2023 | 448,140 |
| CARMONA RICHARD H. M.D. | Director | Stock Award(Grant) | Dec 17, 2023 | 157,369 |
| GRANGER ELDER | Director | Stock Award(Grant) | Dec 17, 2023 | 39,601 |
| KARBE FRANK L | Chief Executive Officer | Stock Award(Grant) | Dec 17, 2023 | 526,516 |
| LAVIZZO-MOUREY RISA J | Director | Stock Award(Grant) | Dec 17, 2023 | 13,750 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 1.08% | 438,479 | 473.56K | Jun 29, 2023 |
| Farallon Capital Management Llc | 0.81% | 330,619 | 357.07K | Jun 29, 2023 |
| Geode Capital Management, LLC | 0.30% | 121,724 | 131.46K | Jun 29, 2023 |
| Blackrock Inc. | 0.22% | 90,390 | 97.62K | Jun 29, 2023 |
| State Street Corporation | 0.11% | 45,200 | 48.82K | Jun 29, 2023 |
| Ameriprise Financial, Inc. | 0.04% | 15,000 | 16.20K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.80% | 326,043 | 352.13K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 0.28% | 112,436 | 121.43K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.08% | 32,063 | 22.45K | May 30, 2023 |
| iShares Micro Cap ETF | 0.08% | 30,928 | 19.18K | Aug 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.03% | 13,172 | 9.22K | May 30, 2023 |
| Fidelity NASDAQ Composite Index Fund | 0.02% | 6,986 | 4.89K | May 30, 2023 |